Dr. Clarke was promoted to Chief Executive Officer of Pulmatrix in 2012 after serving as the Chief Scientific Officer. Joining Pulmatrix in 2004 as the first PhD level scientist, his role evolved to oversight of Research and Development efforts at Pulmatrix focused on developing the Pulmatrix technologies for treatment of respiratory disease. He has helped raise greater than $60 million in venture capital funding for the company as well as secured more than $10 million in non-dilutive funding to support Pulmatrix R&D programs. Previous to Pulmatrix, he was an Associate Director of Life Sciences at Alkermes, Inc. focused mainly on developing inhaled therapeutic products with the AIR® technology platform. Dr. Clarke holds a B.Sc. in Biomedical Engineering from Boston University, has his Ph.D. in Physiology from Johns Hopkins University, and completed his post-doctoral training in Respiratory Biology at Brigham and Women’s Hospital and Harvard University. Dr. Clarke has over a dozen years industry and over 20 years total experience focused on pulmonary drug delivery and the role of inhaled particles in respiratory biology and medicine leading to co-authorship of over 80 chapters, papers, and abstracts.
As CSO, Dr. Hava leads the Research and Development organization in the development of iSPERSE dry powder delivery platform. In addition, Dr. Hava directs and manages the company’s therapeutic strategy to identify and prioritize drug targets and drugs that are enabled by the iSPERSE dry powder delivery platform. Dr. Hava joined Pulmatrix in 2006 as one of the first Senior Scientists and has been involved in the early stage research and development programs that identified and characterized several of the key aspects of the Pulmatrix technology. Dr. Hava earned his PhD. in Molecular Biology and Microbiology at Tufts University and completed his post-doctoral training studying immunology and host-pathogen interactions at Harvard Medical School. Dr. Hava has co-authored over 20 papers and abstracts focused on pulmonary infectious disease, immunology and chronic lung diseases.
Katie Kane Director Regulatory Affairs and Clinical Operations
Ms. Kane is responsible for the global regulatory strategy for Pulmatrix’s drug candidates, and leads the clinical operations for all clinical trials. She has fifteen years of experience in the regulatory and clinical fields for biotech companies, working with small molecules, biologics and medical devices. Prior to joining Pulmatrix in 2007, she worked in Regulatory Affairs at Array BioPharma Inc. and has previously held positions at CBR International, Mitek Worldwide and Organogenesis Inc. She has experience in developing drugs, and in particular early-phase regulatory and clinical interactions, in the respiratory, oncology, inflammation, dermatology, orthopedic, plastic and reconstructive therapeutic areas.
Ms. Kane has a B.S. in Biology from Boston College.
Dr. Sung has spent over a decade developing novel particle engineering and formulation technologies to advance respiratory dry powder drug delivery. Dr. Sung joined Pulmatrix in 2008, leading the formulation, process, particle engineering and analytical chemistry development functions. Prior to her graduate studies, Dr. Sung was an early employee at Advanced Inhalation Research (AIR®) Inc. and later Alkermes, Inc. after the acquisition of AIR, where she advanced formulation development of the pulmonary drug delivery platform technology across small molecule and macromolecule therapies. Dr. Sung has numerous scientific publications and patents/applications in drug delivery, primarily focused on particle formulations for inhaled therapeutics. Dr. Sung has a S.B. in Chemical Engineering from Massachusetts Institute of Technology and holds a Ph.D. and M.S. in Engineering Sciences with a focus on Biomedical Engineering from Harvard University.